AYTU BioPharma agrees to $2.70-a-share Rosemont buyout
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
AYTU BioPharma reported net revenue of $14.842 million for the three months ended September 30, 2026, up 6.9% from $13.888 million a year earlier. EXXUA generated $4.9 million; ADHD Portfolio revenue fell to $7.737 million from $13.156 million, while Pediatric Portfolio revenue rose to $2.205 million from $0.715 million. Gross profit margin was 64%, compared with 66%.
AYTU recorded a $3.881 million net loss, versus $1.965 million net income a year earlier. Operating activities used $275,000 in cash. Cash and cash equivalents were $25.494 million as of September 30, 2026, with $5.1 million available under the revolving credit facility. Management believes cash, operating cash flows and credit availability will fund operations and obligations for at least 12 months.
On November 16, 2026, AYTU entered an agreement for Rosemont to acquire all outstanding common shares through a $2.70-per-share cash tender offer, followed by a merger making AYTU a wholly owned subsidiary. Closing is subject to customary conditions, including tender of a majority of outstanding shares; the parties expect it by calendar year-end, subject to satisfaction or waiver of conditions. Completion is expected to repay and terminate the Eclipse Agreement, including applicable early termination fees, and accelerate unrecognized stock-based compensation.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNet revenue rose 6.9% to $14.842 million in the September quarter.
- Moderate pointOperating cash use narrowed to $275,000 from $618,000 a year earlier.
Negative
- Moderate pointNet results swung to a $3.881 million loss from $1.965 million income.
Filing Explained
AYTU reports $100 million left on its shelf, but that registration is future-sale capacity, not completed financing.
The 10-Q says the Rosemont transaction remains subject to closing conditions; while it is pending, AYTU cannot issue equity or incur additional debt without Rosemont’s consent.
AYTU reports
Key Figures
Key Terms
gross-to-net realization financial
SOFR financial
borrowing base financial
derivative warrant liabilities financial
prefunded warrants financial
right-of-use assets technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of AYTU's deal with Rosemont?
How did AYTU's revenue change in the September 2026 quarter?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
For the quarterly period ended
or
For the transition period from __________ to ___________
Commission File Number:

AYTU BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
| | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| | ( |
| (Address of principal executive offices and zip code) | (Registrant’s telephone number, including area code) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| | | The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| | ☒ | Smaller reporting company | |
| Emerging growth company | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes
As of November 9, 2026, the registrant had
AYTU BIOPHARMA, INC.
FORM 10-Q
TABLE OF CONTENTS
| Page |
||
| Cautionary Information Regarding Forward-Looking Statements | 4 | |
| PART I - FINANCIAL INFORMATION | 5 | |
| Item 1. | Financial Statements |
5 |
| Unaudited Condensed Consolidated Balance Sheets |
5 |
|
| Unaudited Condensed Consolidated Statements of Operations |
6 |
|
| Unaudited Condensed Consolidated Statements of Stockholders’ Equity |
7 |
|
| Unaudited Condensed Consolidated Statements of Cash Flows |
8 |
|
| Notes to the Unaudited Condensed Consolidated Financial Statements |
9 |
|
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
30 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
37 |
| Item 4. | Controls and Procedures |
37 |
| PART II - OTHER INFORMATION | 38 | |
| Item 1. | Legal Proceedings |
38 |
| Item 1A. | Risk Factors |
38 |
| Item 5. | Other Information | 38 |
| Item 6. | Exhibits |
38 |
| SIGNATURES | 39 |
|
CAUTIONARY INFORMATION REGARDING FORWARD-LOOKING STATEMENTS
This Report on Form 10-Q (“Form 10-Q” or “this report”) includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this report, including statements regarding our regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “potential,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation: our anticipated future cash position; the planned expanded commercialization of our products and the potential future commercialization of our product candidates; our anticipated future growth rates; anticipated sales increases; anticipated net revenue increases; amounts of certain future expenses and cost of goods sold; our plans to acquire additional assets or dispose of assets, anticipated increases or decreases to operating expenses, and selling, general, and administrative expenses; future events under our current and potential future collaborations; and the proposed acquisition of the Company by Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”), including the anticipated timing and consummation of the tender offer (the “Offer”) and the subsequent merger (the “Merger” and, together with the Offer, the “Transaction”) and the satisfaction or waiver of the conditions to the Transaction.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation the risks described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10‑K for the year ended June 30, 2026 (“2026 Form 10-K”), and in the reports we file with the United States Securities and Exchange Commission (“SEC”). These risks are not exhaustive. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We can provide no assurance that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements.
This Form 10-Q may refer to registered trademarks that we currently own or license, such as Aytu, Aytu BioPharma, Aytu RxConnect, Neos Therapeutics, EXXUA, Adzenys, Adzenys ER, Adzenys XR-ODT, Cotempla, Cotempla XR-ODT, and Karbinal, which are protected under applicable intellectual property laws and are our property or the property of our subsidiaries. This Form 10-Q also contains trademarks, service marks, copyrights and trade names of other companies, which are the property of their respective owners. Solely for convenience, our trademarks and tradenames referred to in this Form 10-Q may appear without the ® or ™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames. We obtained statistical data, market and product data, and forecasts used throughout this Form 10-Q from market research, publicly available information and industry publications.
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
AYTU BIOPHARMA, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
| September 30, | June 30, | |||||||
| 2026 | 2026 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Inventories | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Non-current assets: | ||||||||
| Property and equipment, net | ||||||||
| Operating lease right-of-use assets | ||||||||
| Intangible assets, net | ||||||||
| Other non-current assets | ||||||||
| Total non-current assets | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities | ||||||||
| Revolving credit facility | ||||||||
| Current portion of debt | ||||||||
| Other current liabilities | ||||||||
| Total current liabilities | ||||||||
| Non-current liabilities: | ||||||||
| Debt, net of current portion | ||||||||
| Derivative warrant liabilities | ||||||||
| Other non-current liabilities | ||||||||
| Total non-current liabilities | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (note 13) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, par value $0.0001; 50,000,000 shares authorized; no shares issued or outstanding | ||||||||
| Common stock, par value $0.0001; 200,000,000 shares authorized; 10,868,208 and 10,728,208 shares issued and outstanding as of September 30, 2026, and June 30, 2026, respectively | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
The accompanying notes to the unaudited condensed consolidated financial statements are an integral part of this statement.
AYTU BIOPHARMA, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net revenue | $ | $ | ||||||
| Cost of goods sold | ||||||||
| Gross profit | ||||||||
| Operating expenses: | ||||||||
| Selling and marketing | ||||||||
| General and administrative | ||||||||
| Amortization of intangible assets | ||||||||
| Total operating expenses | ||||||||
| Loss from operations | ( | ) | ( | ) | ||||
| Other income, net | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Derivative warrant liabilities gain | ||||||||
| Total other income (expense), net | ||||||||
| (Loss) income before income tax expense | ( | ) | ||||||
| Income tax (expense) benefit | ||||||||
| Net (loss) income | $ | ( | ) | $ | ||||
| Basic weighted-average common shares outstanding (note 17) | ||||||||
| Diluted weighted-average common shares outstanding (note 17) | ||||||||
| Net (loss) income per share (note 17): | ||||||||
| Basic - net (loss) income | $ | ( | ) | $ | ||||
| Diluted - net (loss) income | $ | ( | ) | $ | ( | ) | ||
The accompanying notes to the unaudited condensed consolidated financial statements are an integral part of this statement.
AYTU BIOPHARMA, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share data)
| Additional | Total | |||||||||||||||||||
| Common Stock | Paid-in | Accumulated | Stockholders’ | |||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balances, June 30, 2026 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Stock-based compensation expense and issuance of restricted stock, net of forfeitures | ||||||||||||||||||||
| Net loss | — | ( | ) | ( | ) | |||||||||||||||
| Balances, September 30, 2026 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Additional | Total | |||||||||||||||||||
| Common Stock | Paid-in | Accumulated | Stockholders’ | |||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balances, June 30, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Stock-based compensation expense | — | — | ||||||||||||||||||
| Issuance of common stock from exercise of warrants | — | — | ||||||||||||||||||
| Net income | — | |||||||||||||||||||
| Balances, September 30, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
The accompanying notes to the unaudited condensed consolidated financial statements are an integral part of this statement.
AYTU BIOPHARMA, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net (loss) income | $ | ( | ) | $ | ||||
| Adjustments to reconcile net (loss) income to net cash from operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Stock-based compensation expense | ||||||||
| Derivative warrant liabilities gain | ( | ) | ( | ) | ||||
| Amortization of debt discount and issuance costs | ||||||||
| Inventory write-down | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | ( | ) | ||||||
| Inventories | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Other operating assets | ||||||||
| Accounts payable | ||||||||
| Accrued liabilities | ( | ) | ( | ) | ||||
| Other operating liabilities | ( | ) | ||||||
| Net cash from operating activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Net (repayments) borrowings on revolving credit facility | ( | ) | ||||||
| Payments made on fixed payment arrangements | ( | ) | ||||||
| Payments made to borrowings | ( | ) | ( | ) | ||||
| Net cash from financing activities | ( | ) | ||||||
| Net change in cash and cash equivalents | ( | ) | ||||||
| Cash and cash equivalents at beginning of period | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for income taxes | $ | $ | ||||||
The accompanying notes to the unaudited condensed consolidated financial statements are an integral part of this statement.
AYTU BIOPHARMA, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Note 1 - Nature of Business and Financial Condition
Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”), is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system (“CNS”) diseases to improve the quality of life for patients. The Company was originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, the Company changed its name to Aytu BioPharma, Inc.
The Company’s strategy is to become a leading pharmaceutical company that improves the lives of patients. The Company uses a focused approach of in-licensing, acquiring, developing and commercializing novel prescription therapeutics in order to continue building its portfolio of revenue-generating products and leveraging its commercial team’s expertise to build leading brands within large therapeutic markets. In June 2025, the Company entered into an Exclusive Commercialization Agreement (the “Commercialization Agreement”) with Fabre-Kramer Holdings, Inc. (“Fabre-Kramer”) to commercialize EXXUA (gepirone) extended-release tablets (“EXXUA”) in the United States. Gepirone is a new chemical entity and the Company believes EXXUA to be a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the United States Food and Drug Administration (“FDA”) for the treatment of major depressive disorder (“MDD”) in adults. In fiscal 2026, the Company began selling EXXUA and made it the centerpiece of its commercial efforts.
In addition, the Company will continue to focus on commercializing innovative prescription products that address CNS conditions, including attention deficit hyperactivity disorder (“ADHD”). The Company is focusing its efforts on accelerating the growth of its commercial business and achieving positive operating cash flows. To achieve these goals, the Company indefinitely suspended active development of its clinical development programs and has wound down and divested unprofitable operations.
The Company’s business is focused on the commercialization of its prescription pharmaceutical products sold primarily through third-party wholesalers, distributors and pharmacies and which primarily consists of three product portfolios. The first consists of EXXUA for the treatment of MDD, the second consists of products for the treatment of ADHD (the “ADHD Portfolio”) and the third consists of a line of legacy products (the “Pediatric Portfolio”). The Company contracts with contract manufacturing organizations (“CMOs”) for the manufacture and testing of all of its products.
In September 2024, the Company entered into an exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd (“Lupin”), a subsidiary of global pharmaceutical company Lupin Limited, for Lupin to commercialize Adzenys and Cotempla in Canada. The Company will supply Adzenys and Cotempla to Lupin based on forecasts and provide various product commercialization, regulatory and quality assurance resources. Lupin is responsible for seeking local regulatory approvals and marketing authorizations for both Adzenys and Cotempla, which is expected to occur within the next year.
Note 2 - Summary of Significant Accounting Policies
Principles of Consolidation
The Company’s unaudited condensed consolidated financial statements and notes thereto include the accounts of its wholly owned subsidiaries Aytu Therapeutics, LLC and Neos Therapeutics, Inc. (“Neos”) and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
Basis of Presentation
The unaudited condensed consolidated financial statements and notes thereto contained in this Form 10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s 2026 Form 10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited condensed consolidated financial statements and notes thereto contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as of June 30, 2026, was derived from the audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The results of operations for the three months ended September 30, 2026, are not necessarily indicative of expected operating results for the full year or any future period. Certain prior-period amounts have been reclassified to conform to the current-period presentation. These reclassifications had no effect on previously reported net income, net income per share, total assets, total liabilities, total stockholders’ equity, accumulated deficit, or net cash from operating activities.
Use of Estimates
The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. In the accompanying unaudited condensed consolidated financial statements and notes thereto, estimates are used for, but not limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use (“ROU”) assets and lease liabilities; valuation of financial instruments, warrants and derivative warrant liabilities, intangible assets, and long-lived assets; depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. The Company periodically evaluates estimates used in the preparation of the financial statements for reasonableness.
Segment Information
Operating segments are identified as components that engage in business activities from which they may earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company’s chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the respective segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company determined that it operates as a single operating and reportable segment. The Company’s CODM is its Chief Executive Officer, who manages operations and regularly reviews the financial information of the Company’s operations as a single operating segment for the purposes of allocating resources and evaluating its financial performance.
The CODM reviews net income or loss as a measure of segment profit or loss in assessing performance and allocating resources. Segment revenues, expenses and profit or loss are reported on the unaudited condensed consolidated statements of operations, with particular emphasis on net revenue by product portfolio (see Note 3 - Revenue for net revenue disaggregated by product portfolio). Additionally, the measure of segment assets is reported on the Company’s unaudited condensed consolidated balance sheet as total assets, with particular emphasis on the Company’s available liquidity and working capital, including its cash and cash equivalents, accounts receivable, net, inventories and current liabilities. As of September 30, 2026, and June 30, 2026, all long-lived assets were domiciled within the United States.
Warrants
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC Topic 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable.
Income Taxes
The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. In July 2025, the One Big Beautiful Bill Act (the “OBBBA”) was enacted in the United States. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act (the “TCJA”), allowing for accelerated tax deductions for qualified property and research expenditures, and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in calendar year 2025 and others implemented through calendar year 2027. The income tax provision considers the impacts to the Company’s deferred tax assets and liabilities on the unaudited condensed consolidated balance sheet as of September 30, 2026, including deferred tax assets for interest, fixed assets, and Section 174 capitalization. There have been no changes in tax law affecting the tax provision during the three months ended September 30, 2026.
For the three months ended September 30, 2026, and 2025, there was
An ownership change has limited the Company’s ability to offset, post-change, United States federal taxable income. Section 382 of the Internal Revenue Code of 1986, as amended (the “IRC”), imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Company’s ability to use the change in control net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the zero percent effective tax rate.
The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized.
The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the unaudited condensed consolidated statements of operations.
Recent Accounting Pronouncements Not Yet Adopted
In November 2024, the FASB issued Accounting Standards Update (“ASU”) No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). The amendments in ASU 2024-03 require public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the impact the adoption of ASU 2024-03 may have on the Company’s consolidated financial statements and disclosures.
In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities (“ASU 2025-10”), to provide guidance on how business entities should recognize, measure, and present government grants received. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted, and the amendments may be applied using a modified prospective, modified retrospective, or full retrospective adoption. The Company is currently evaluating the impact the adoption of ASU 2025-10 may have on the Company’s consolidated financial statements and disclosures.
In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”), which is intended to improve the navigability of the guidance in ASC 270, Interim Reporting, and clarify when it applies. Under the amendments, an entity is subject to ASC 270 if it provides interim financial statements and notes in accordance with U.S. GAAP. ASU 2025-11 also addresses the form and content of such financial statements, interim disclosures requirements, and establishes a principle under which an entity must disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the impact the adoption of ASU 2025-11 may have on the Company’s consolidated financial statements and disclosures.
As of September 30, 2026, and through the filing of this report, no other accounting guidance applicable to the Company has been issued and not yet adopted in fiscal 2027 that would have a material effect on the Company’s unaudited condensed consolidated financial statements and related disclosures. For a complete set of the Company’s significant accounting policies, refer to the audited consolidated financial statements and notes thereto included in the Company’s 2026 Form 10-K.
Note 3 - Revenue
Net revenue primarily consists of sales of prescription pharmaceutical products from EXXUA, the ADHD Portfolio and the Pediatric Portfolio, principally to a limited number of wholesale distributors and pharmacies in the United States. Net revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally “free-on-board” destination when shipped domestically within the United States, consistent with contractual terms.
Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company’s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and does not believe variances between actual and estimated amounts have been material.
Net Revenue by Product Portfolio
Net revenue disaggregated by product portfolio for the three months ended September 30, 2026, and 2025, was as follows:
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| (in thousands) | ||||||||
| EXXUA | $ | $ | ||||||
| ADHD Portfolio | ||||||||
| Pediatric Portfolio | ||||||||
| Other | ||||||||
| Total net revenue | $ | $ | ||||||
Other includes net revenue from various discontinued or deprioritized products.
Net Revenue by Geographic Location
The Company’s net revenue is predominantly within the United States, with insignificant international sales.
Note 4 - Inventories
Inventories consist of raw materials, work in process and finished goods, and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no alternate uses for the inventory, the Company will record a charge to cost of goods sold to reduce the value of the inventory to net realizable value in the period the impairment is identified.
The Company incurred inventory write-downs primarily as a result of unsaleable and slow-moving products of $
Inventories consist of the following:
| September 30, | June 30, | |||||||
| 2026 | 2026 | |||||||
| (in thousands) | ||||||||
| Raw materials | $ | $ | ||||||
| Work in process | ||||||||
| Finished goods | ||||||||
| Inventories | $ | $ | ||||||
Note 5 - Property and Equipment
Property and equipment are recorded at cost and depreciated on a straight-line basis over the assets’ estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term. Depreciation and amortization expense from property and equipment was less than $
Property and equipment, net, consist of the following:
| September 30, | June 30, | |||||||
| 2026 | 2026 | |||||||
| (in thousands) | ||||||||
| Manufacturing and lab equipment | $ | $ | ||||||
| Office equipment, furniture and other | ||||||||
| Leasehold improvements | ||||||||
| Property and equipment, gross | ||||||||
| Less: accumulated depreciation and amortization | ( | ) | ( | ) | ||||
| Property and equipment, net | $ | $ | ||||||
Note 6 - Leases
The Company’s operating leases are for its offices, and these leases have original lease periods expiring between 2029 and 2030. Most leases include option provisions under which the parties may extend the lease term. The Company’s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. The Company has
In June 2024, the Company entered into a forward-starting operating lease agreement with the owner of its office space in Berwyn, Pennsylvania to lease the same premises that the Company had previously occupied under a sublease arrangement. The Company determined that it is an operating lease, and that lease commencement occurred in July 2024. The initial lease termination date is July 31, 2030, and under the lease agreement the Company has one five-year renewal option to extend the lease through July 2035. The Company has elected to utilize the practical expedient to not separate lease and non-lease components upon recognition and variable lease payments will be expensed as incurred. The Company recorded an operating lease ROU asset of $
In May 2023, the Company entered into an operating lease agreement to relocate its principal office from Englewood, Colorado to Denver, Colorado. The initial lease termination date is March 31, 2029, and under the lease agreement the Company has one five-year renewal option to extend the lease through March 2034. Undiscounted minimum monthly rent payments average approximately $
The components of lease costs are as follows:
| Three Months Ended | |||||||||
| September 30, | |||||||||
| 2026 | 2025 | Statement of Operations Classification | |||||||
| (in thousands) | |||||||||
| Lease cost: | |||||||||
| Operating lease cost | $ | $ | Operating expenses | ||||||
| Short-term lease cost | Operating expenses | ||||||||
| Total lease cost | $ | $ | |||||||
Supplemental balance sheet information related to leases is as follows:
| September 30, | June 30, | ||||||||
| 2026 | 2026 | Balance Sheet Classification | |||||||
| (in thousands) | |||||||||
| Assets: | |||||||||
| Non-current: operating leases | $ | $ | Operating lease right-of-use assets | ||||||
| Liabilities: | |||||||||
| Current: operating leases | $ | $ | Other current liabilities | ||||||
| Non-current: operating leases | Other non-current liabilities | ||||||||
| Total lease liabilities | $ | $ | |||||||
The remaining weighted-average lease term and discount rate used are as follows:
| September 30, | June 30, | |||||||
| 2026 | 2026 | |||||||
| Weighted-average remaining lease term (years): | ||||||||
| Operating leases | ||||||||
| Weighted-average discount rate: | ||||||||
| Operating leases | % | % | ||||||
Operating cash outflows from operating leases were $
As of September 30, 2026, the Company’s estimated future minimum lease payments are as follows:
| Estimated Future Minimum Lease Payments | ||||
| (in thousands) | ||||
| 2027 (remaining 9 months) | $ | |||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| 2031 | ||||
| Total lease payments | ||||
| Less: imputed interest | ( | ) | ||
| Total lease liabilities | $ | |||
Note 7 - Intangible Assets
A summary of the Company’s intangible assets, all of which are definite-lived intangible assets, as of September 30, 2026, and June 30, 2026, is as follows:
| September 30, 2026 | ||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Weighted-Average Remaining Life | |||||||||||||
| (in thousands) | (in years) | |||||||||||||||
| Product technology rights | $ | $ | ( | ) | $ | |||||||||||
| Technology rights | ( | ) | ||||||||||||||
| Commercialization rights | ( | ) | 3.9 | |||||||||||||
| Total intangible assets | $ | $ | ( | ) | $ | |||||||||||
| June 30, 2026 | ||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Weighted-Average Remaining Life | |||||||||||||
| (in thousands) | (in years) | |||||||||||||||
| Product technology rights | $ | $ | ( | ) | $ | |||||||||||
| Technology rights | ( | ) | ||||||||||||||
| Commercialization rights | ( | ) | ||||||||||||||
| Total intangible assets | $ | $ | ( | ) | $ | |||||||||||
Gross carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period. Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. Renewal periods generally range from approximately
Amortization expense of intangible assets included in the unaudited condensed consolidated statements of operations for the three months ended September 30, 2026, and 2025, is set forth in the below table:
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| (in thousands) | ||||||||
| Statement of operations classification: | ||||||||
| Cost of goods sold | $ | $ | ||||||
| Operating expenses | ||||||||
| Total amortization of intangible assets expense | $ | $ | ||||||
As of September 30, 2026, the Company’s estimated future amortization expense is as follows:
| Estimated Future Amortization Expense | ||||
| (in thousands) | ||||
| 2027 (remaining 9 months) | $ | |||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| 2031 | ||||
| Thereafter | ||||
| Total future amortization expense | $ | |||
Product Technology Rights
The product technology rights are related to the rights to production, supply and distribution agreements of various products.
ADHD Portfolio
The Company has developed product technology rights related to the production and sale of Adzenys and Cotempla. The formulations for the ADHD products are protected by patented technology. As of September 30, 2026, the estimated remaining economic life of these proprietary product technology rights is
Technology Rights
TRRP Proprietary Technology
The Company has time release resin particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlies each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well. As of September 30, 2026, the estimated remaining economic life of these proprietary technology rights is
Commercialization Rights
As part of the Commercialization Agreement for the exclusive commercialization rights of EXXUA in the United States, the Company capitalizes to the carrying value of intangible assets any contingent payments made that are considered a part of the Commercialization Agreement’s total consideration and which are not within the scope of derivative guidance once the contingencies related to these payments are resolved. In December 2025, the commercialization rights were considered placed in service commensurate with the launch date of EXXUA. The Company began amortizing the commercialization rights on a straight-line basis over the estimated life of the asset and, if necessary, the Company will adjust the carrying value of the commercialization rights on a cumulative catch-up basis for any future payments as if the additional capitalized amount had been capitalized on the same date that the intangible was placed in service. As of September 30, 2026, the estimated remaining economic life of the EXXUA commercialization rights is
Note 8 - Accrued Liabilities
Accrued liabilities consist of the following:
| September 30, | June 30, | |||||||
| 2026 | 2026 | |||||||
| (in thousands) | ||||||||
| Accrued savings offers | $ | $ | ||||||
| Return reserve | ||||||||
| Accrued program liabilities | ||||||||
| Accrued customer and product related fees | ||||||||
| Accrued employee compensation | ||||||||
| Other accrued liabilities | ||||||||
| Total accrued liabilities | $ | $ | ||||||
Accrued savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. The return reserve represents the Company’s accrual for estimated product returns. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued distributor fees, accrued royalties, and other product-related fees and deductions. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. Other accrued liabilities consist of various other accruals, none of which individually or in the aggregate represent greater than five percent of total liabilities.
Note 9 - Other Liabilities
Other liabilities consist of the following:
| September 30, | June 30, | |||||||
| 2026 | 2026 | |||||||
| (in thousands) | ||||||||
| Employee retention credit (1) | $ | $ | ||||||
| Operating lease liabilities (2) | ||||||||
| Other (3) | ||||||||
| Total other liabilities | ||||||||
| Less: current portion of other liabilities | ( | ) | ( | ) | ||||
| Total non-current portion of other liabilities | $ | $ | ||||||
| (1) | The $ |
| (2) | The Company has entered into various operating lease agreements for certain of its offices. See Note 6 - Leases for further detail. |
| (3) | Other consists of taxes payable, deferred cost related to the Company’s technology transfer, and various other accruals, none of which individually or in the aggregate represent greater than five percent of total liabilities. |
Note 10 - Revolving Credit Facility
On June 20, 2025, the Company and certain of its subsidiaries entered into an Amendment No. 6 to Loan and Security Agreement (the “Eclipse Amendment No. 6”) to the loan and security agreement dated October 2, 2019, as amended by Amendment No. 1, dated March 19, 2021; Amendment No. 2, dated January 26, 2022; Amendment No. 3, dated June 1, 2022; Amendment No. 4, dated March 24, 2023; and Amendment No. 5, dated June 12, 2024 (together the “Eclipse Agreement”), with Eclipse Business Capital LLC (“Eclipse”), as agent, and the lenders party thereto (agent and such lenders, collectively, the “Eclipse Lender”). Under the Eclipse Agreement, the Company has two loan agreements, a term loan (the “Eclipse Term Loan”), which is described further in Note 11 - Debt, and a revolving credit facility (the “Eclipse Revolving Loan”).
The Eclipse Revolving Loan has a potential maximum borrowing base of $
In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i)
The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the Eclipse Agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of September 30, 2026, the Company was in compliance with the covenants under the Eclipse Agreement. The Company’s obligations under the Eclipse Agreement are secured by substantially all of the Company’s assets, as defined further in the Eclipse Agreement.
As of September 30, 2026, there was $
Note 11 - Debt
On June 20, 2025, the Company and certain of its subsidiaries entered into Eclipse Amendment No. 6, which provided for, among other things, an increase in the Eclipse Term Loan principal amount to $
The Eclipse Term Loan incurs interest at a rate of the SOFR plus
In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i)
The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the Eclipse Agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make certain asset sales without the prior written consent of the Eclipse Lender. A failure to comply with these covenants could permit the Eclipse Lender to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of September 30, 2026, the Company was in compliance with the covenants under the Eclipse Agreement.
As of September 30, 2026, there was $
Debt consists of the following:
| September 30, | June 30, | |||||||
| 2026 | 2026 | |||||||
| (in thousands) | ||||||||
| Term loan principal amount | $ | $ | ||||||
| Unamortized debt discount and issuance costs | ( | ) | ( | ) | ||||
| Total debt | ||||||||
| Less: current portion of debt | ( | ) | ( | ) | ||||
| Total debt, net of current portion | $ | $ | ||||||
As of September 30, 2026, the Company’s future Eclipse Term Loan principal payments are as follows:
| Future Principal Payments | ||||
| (in thousands) | ||||
| 2027 (remaining 9 months) | $ | |||
| 2028 | ||||
| 2029 | ||||
| Total future principal payments | ||||
| Less: unamortized debt discount and issuance costs | ( | ) | ||
| Less: current portion of debt | ( | ) | ||
| Total debt, net of current portion | $ | |||
Note 12 - Fair Value Measurements
The Company determines the fair value of financial and non-financial assets using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:
| ● | Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to the Company for identical assets or liabilities |
| ● | Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and |
| ● | Level 3: Unobservable inputs that are supported by little or no market activity. |
The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities and current and non-current debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Current and non-current debt are reported at their amortized costs on the Company’s unaudited condensed consolidated balance sheets. The carrying amounts of the Eclipse Term Loan and the Eclipse Revolving Loan approximate their fair value because they bear interest at variable market rates (Level 2). The remaining financial instruments are reported on the Company’s unaudited condensed consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.
Recurring Fair Value Measurements
The following tables present the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2026, and June 30, 2026, by level within the fair value hierarchy:
| Fair Value at | Fair Value Measurements at September 30, 2026 | |||||||||||||||
| September 30, 2026 | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
| (in thousands) | ||||||||||||||||
| Liabilities: | ||||||||||||||||
| Derivative warrant liabilities | $ | $ | $ | $ | ||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| Fair Value at | Fair Value Measurements at June 30, 2026 | |||||||||||||||
| June 30, 2026 | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
| (in thousands) | ||||||||||||||||
| Liabilities: | ||||||||||||||||
| Derivative warrant liabilities | $ | $ | $ | $ | ||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
Cash and cash equivalents in the unaudited condensed consolidated balance sheets include bank deposits and money market funds, and reflect their fair value at Level 1 in the fair value hierarchy.
Summary of Level 3 Input Changes
A summary of changes to those fair value measures using Level 3 inputs is as follows:
| Derivative | ||||
| Warrant Liabilities | ||||
| (in thousands) | ||||
| Balance as of June 30, 2026 | $ | |||
| Change in fair value included in earnings | ( | ) | ||
| Balance as of September 30, 2026 | $ | |||
Significant Assumptions
Beginning with the first quarter of fiscal 2027, the Company values the June 2023 Tranche A Warrants using the Black-Scholes option pricing model rather than a combination of the Monte Carlo simulation and Black-Scholes models, as the Company does not believe the difference in the resulting fair value is material. The valuation methodologies and key assumptions used for the mark-to-market fair value measurements of derivative warrant liabilities as of September 30, 2026, are as follows:
| Tranche A Warrants | Warrants Other (1) | |||||
| Black-Scholes | Black-Scholes | |||||
| Aytu closing stock price | $2.14 | $2.14 | ||||
| Equivalent term (years) | ||||||
| Expected volatility | | | ||||
| Risk-free rate | | | ||||
| Dividend yield | | |
| (1) | Includes all liability classified warrants except the June 2023 Tranche A Warrants (see Note 16 - Warrants for further information). |
Note 13 - Commitments and Contingencies
EXXUA Exclusive Commercialization Agreement
On June 5, 2025, the Company entered into the Commercialization Agreement with Fabre-Kramer, pursuant to which the Company acquired certain rights and obligations in connection with the commercialization of EXXUA in the United States. As consideration for the Commercialization Agreement, the Company made an upfront cash payment of $
The Commercialization Agreement can be terminated at any time upon mutual agreement between the Company and Fabre-Kramer. Either party can terminate the Commercialization Agreement at any time upon written notice for a material default or breach if the material default or breach is not cured within (1)
Pediatric Portfolio
The Company has the exclusive right to distribute and sell certain legacy products in the United States from agreements signed by the Company. The initial term of the agreement was
Legal Matters
Granules Paragraph IV
On October 31, 2024, the Company received a Paragraph IV Certification Notice Letter (the “Notice Letter”) from Granules Pharmaceuticals, Inc. (“Granules”), stating that it intends to market a generic version of Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (“Adzenys”) before the expiration of all patents currently listed in the FDA’s publication of approved drug products with therapeutic equivalence evaluations (the “Orange Book”). The Notice Letter stated that Granules’ abbreviated new drug application (“ANDA”) for the generic version of Adzenys contains a Paragraph IV certification alleging that these patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic version of Adzenys. On December 11, 2024, the Company filed a patent infringement lawsuit against Granules, which triggered a stay precluding the FDA from approving Granules’ ANDA for a generic version of Adzenys for up to 30 months or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. On January 7, 2025, Granules submitted an answer to the complaint. On June 27, 2025, the Court entered a Stipulation And Order Regarding Infringement finding that the submission of Granules’ ANDA infringed multiple claims in each of the Company’s asserted patents. On October 28, 2025, the case was reassigned to visiting judge, Judge Jennifer Choe-Groves of the United States Court of International Trade. This litigation is ongoing, with trial scheduled to begin on January 12, 2027. The Company plans to continue vigorously enforcing its intellectual property rights related to Adzenys.
Revive Investing
The Company had been named as a nominal plaintiff in a lawsuit by two shareholders against Armistice Capital Master Fund, Ltd (“Armistice”), entitled Revive Investing, LLC. et al v. Armistice Master Fund, Ltd. et al, Case 1:20-cv-02849-CMA-TPO, in the United States District Court for the District of Colorado, contending that Armistice was liable for short swing trading profits in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended, for certain trades it made in Company stock in 2019 and 2020 and must disgorge those profits to the Company. That matter proceeded to trial before a jury, which on January 29, 2025, returned a verdict finding no liability. On March 6, 2025, the plaintiffs filed an appeal in the United States Court of Appeals for the Tenth Circuit. As with the original case, regardless of the outcome, this case will not have a material adverse effect upon the Company’s financial condition, results of operations, or cash flows.
Note 14 - Stockholders’ Equity
The Company has
On September 26, 2024, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 15, 2024. This shelf registration statement covers the offering, issuance and sale by the Company of up to an aggregate of $
Note 15 - Equity Incentive Plan
2023 Equity Incentive Plan
On May 18, 2023, the Company’s stockholders approved the adoption of the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the “2023 Equity Incentive Plan”), which replaced all previous plans. On May 21, 2025, the Company’s stockholders approved an amendment (the “Plan Amendment”) to the 2023 Equity Incentive Plan. The Plan Amendment increased the number of shares reserved for issuance under the 2023 Equity Incentive Plan by
During the three months ended September 30, 2026, the Company granted
Stock-Based Compensation Expense
Stock-based compensation expense related to the fair value of stock options, restricted stock and restricted stock units was included in the unaudited condensed consolidated statements of operations as set forth in the below table:
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| (in thousands) | ||||||||
| Selling and marketing | $ | $ | ||||||
| General and administrative | ||||||||
| Total stock-based compensation expense | $ | $ | ||||||
Note 16 - Warrants
The Company has engaged in several different types of equity financings throughout its history, some of which have resulted in the Company issuing warrants and prefunded warrants. Equity classified warrants are valued using a Black-Scholes option pricing model at issuance and are not remeasured. Liability classified warrants are carried at fair value using the Black-Scholes option pricing model. Outstanding warrants that are classified as derivative warrant liabilities in the unaudited condensed consolidated balance sheets are marked to market at each reporting period, with the change in fair value recorded as a gain or loss on remeasurement and reported as a component of cash flows from operations (see Note 12 - Fair Value Measurements for further detail).
The Company determined that public equity offerings completed in June 2023 and June 2025 whereby the Company issued certain warrants and prefunded warrants (collectively, the “June 2023 and June 2025 Warrants”) to certain institutional investors (the “Investors”) included certain stockholder approval language relating to beneficial ownership blockers and Nasdaq Stock Market LLC ownership blockers (the “Blockers”) creating ambiguity that required the Company to classify the June 2023 and June 2025 Warrants as liabilities rather than equity in its financial statements based on applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity and ASC Topic 815, Derivatives and Hedging. The Company and the Investors agreed to make changes to the Blockers to address the unintended accounting treatment in order to provide for equity classification going forward and agreed to amend the June 2023 and June 2025 Warrants.
On March 31, 2026, the Company and the Investors, as applicable, entered into (i) an Amended and Restated June 2023 Tranche A Warrant (“Amended 2023 Tranche A Warrant”), (ii) an Amended and Restated June 2023 Prefunded Warrant (“Amended 2023 Prefunded Warrant”) and (iii) an Amended and Restated June 2025 Prefunded Warrant (“Amended 2025 Prefunded Warrant”), pursuant to which the Company canceled the previously issued June 2023 and June 2025 Warrants and issued to the Investors, as applicable, an Amended 2023 Tranche A Warrant, an Amended 2023 Prefunded Warrant and an Amended 2025 Prefunded Warrant, with revised Blockers. Under the Blockers that were included in the June 2023 and June 2025 Warrants prior to their amendment on March 31, 2026, it was unclear whether the Company’s stockholders could vote to amend or change the Blockers. The amendments clarified that the Blockers could not be amended or modified by a vote of the Company’s stockholders. As a result, the Company concluded that the amended warrants met the requirements for equity classification. Accordingly, the related derivative warrant liabilities of $
The number of warrants and prefunded warrants outstanding as of September 30, 2026, is as follows:
| Remaining | |||||||||||||||
| Number | Exercise | Contractual | |||||||||||||
| Description | Outstanding | Price | Life in Years (5) | Type | Classification | ||||||||||
| January 2022 Warrants (1) | $ | Warrant | Liability | ||||||||||||
| March 2022 Warrants (1) | $ | Warrant | Liability | ||||||||||||
| August 2022 Warrants (1) | $ | Warrant | Liability | ||||||||||||
| June 2023 Tranche A Warrants (2) | $ | Warrant | Liability | ||||||||||||
| Amended 2023 Tranche A Warrants (2) | $ | Warrant | Equity | ||||||||||||
| Amended 2023 Prefunded Warrants (3) | $ | N/A | Prefunded Warrant | Equity | |||||||||||
| Amended 2025 Prefunded Warrants (4) | $ | N/A | Prefunded Warrant | Equity | |||||||||||
| Total outstanding | |||||||||||||||
| (1) | Each of these warrants is exercisable at any time for |
| (2) | In June 2023, the Company issued these tranche A warrants to purchase |
| (3) | As discussed above, on March 31, 2026, a total of |
| (4) | In June 2025, the Company raised gross proceeds of $ |
| (5) | All of the Company’s prefunded warrants do not have an expiration date. |
There were
Note 17 - Earnings Per Share
Basic net income or loss per share is calculated by dividing net income or loss available to common stockholders by the basic weighted-average number of common shares outstanding for the respective period, which includes equity classified prefunded warrants. Equity classified prefunded warrants are included in the computation of the basic weighted-average number of common shares outstanding since the exercise price is negligible and all of the equity classified prefunded warrants are fully vested and exercisable.
Diluted net income or loss per share is calculated by dividing adjusted net income or loss by the diluted weighted-average number of common shares outstanding, which includes the effect of potentially dilutive securities. Potentially dilutive securities for this calculation consist of warrants to purchase common stock that are either liability classified or equity classified, prefunded warrants to purchase common stock that are liability classified, stock options, unvested restricted stock and unvested restricted stock units (see Note 15 - Equity Incentive Plan and Note 16 - Warrants for further detail). If the Company’s adjusted numerator for net income divided by the diluted weighted-average number of common shares outstanding for each potentially dilutive security was greater than the net income per share, then the Company did not include those common equivalent shares in the computation of diluted net income or loss per share because the effect would have been anti-dilutive.
The following is a reconciliation of the numerator and the denominator used in the basic per share calculations:
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| (in thousands, except share and per share data) | ||||||||
| BASIC | ||||||||
| Numerators: | ||||||||
| Net (loss) income | $ | ( | ) | $ | ||||
| Denominator: | ||||||||
| Basic weighted-average common shares outstanding | ||||||||
| Basic per share calculations: | ||||||||
| Net (loss) income per share | $ | ( | ) | $ | ||||
The following is a reconciliation of the numerator and the denominator used in the diluted per share calculations:
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| (in thousands, except share and per share data) | ||||||||
| DILUTED | ||||||||
| Numerators: | ||||||||
| Adjusted numerator - net loss (1) | $ | ( | ) | $ | ( | ) | ||
| Denominator: | ||||||||
| Basic weighted-average common shares outstanding | ||||||||
| Dilutive effect of warrants to purchase common stock | ||||||||
| Diluted weighted-average common shares outstanding | ||||||||
| Diluted per share calculations: | ||||||||
| Net loss per share | $ | ( | ) | $ | ( | ) | ||
| (1) | The net income numerator has been adjusted to remove a gain of $ |
The following table sets forth securities that could be considered anti-dilutive, and therefore are excluded from the calculation of diluted weighted-average common shares outstanding and related per share calculations:
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Warrants to purchase common stock - liability classified (note 16) | ||||||||
| Warrants to purchase common stock - equity classified (note 16) | ||||||||
| Weighted-average of warrants exercised to common stock (note 16) | ||||||||
| Outstanding stock options (note 15) | ||||||||
| Unvested restricted stock (note 15) | ||||||||
| Total anti-dilutive securities | ||||||||
Note 18 - License Agreements
Teva
On December 21, 2018, the Company and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of one of the Company’s ADHD products under an ANDA filed by Teva beginning on July 1, 2026. The ANDA was approved by the FDA on June 19, 2020. As of September 30, 2026, and through the date of this report, Teva has not launched its generic version.
Actavis
On October 17, 2017, the Company entered into an agreement granting Actavis Laboratories FL, Inc. (“Actavis”) (which is now owned by Teva Pharmaceutical Industries Limited) a non-exclusive license to certain patents owned by the Company by which Actavis has the right to manufacture and market its generic version of one of the Company’s ADHD products under its ANDA beginning on September 1, 2025. The ANDA was approved by the FDA on June 22, 2023. Teva launched a generic version of this ADHD product late in the second quarter of fiscal 2026.
Note 19 - Subsequent Events
On November 16, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”) and a wholly owned subsidiary of Rosemont. Pursuant to the Merger Agreement, Rosemont will commence a cash tender offer (the “Offer”) to acquire all outstanding shares of the Company’s common stock at a price of $
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This discussion should be read in conjunction with the Company’s 2026 Form 10-K. The following discussion and analysis contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements, including with respect to the proposed acquisition of the Company, the anticipated timing and consummation of the tender offer and merger, the satisfaction or waiver of the conditions to the consummation of the proposed transaction, and the possibility that the proposed transaction may be delayed or may not be completed at all. For additional information regarding these risks and uncertainties, please see the risk factors included in the Company’s 2026 Form 10-K, and in Part II, Item 1A of this Form 10-Q.
Objective
The purpose of the Management’s Discussion and Analysis (the “MD&A”) is to present information that management believes is relevant to an assessment and understanding of our results of operations and cash flows for the three months ended September 30, 2026, and our financial condition as of September 30, 2026. The MD&A is provided as a supplement to, and should be read in conjunction with, our unaudited condensed consolidated financial statements and notes thereto.
Overview
We are a pharmaceutical company focused on advancing innovative medicines for complex CNS diseases to improve the quality of life for patients. Our strategy is to become a leading pharmaceutical company that improves the lives of patients. We use a focused approach of in-licensing, acquiring, developing and commercializing novel prescription therapeutics in order to continue building our portfolio of revenue-generating products and leveraging our commercial team’s expertise to build leading brands within large therapeutic markets. In June 2025, we entered into the Commercialization Agreement with Fabre-Kramer to commercialize EXXUA in the United States. Gepirone is a new chemical entity, and we believe EXXUA to be a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for the treatment of MDD in adults.
EXXUA has been extensively studied in over 5,000 patients and represents a new class of therapeutics to compete in the United States prescription MDD market. We believe EXXUA can become a very important treatment option for the estimated 21 million Americans affected by MDD. Over 360 million antidepressant prescriptions were written in 2025 in the United States, yet significant unmet needs remain considering the unacceptable side effects associated with current therapeutics. Importantly, we believe that EXXUA is the only antidepressant acting on serotonin receptors that does not carry a label warning about the risk of sexual dysfunction. The mechanism of the antidepressant effect of EXXUA is believed to be related to its modulation of serotonin activity and, specifically, its exclusive and strong binding affinity for 5HT1a receptors, which are key regulators of mood and emotion. EXXUA is not a Selective Serotonin Reuptake Inhibitor (“SSRI”) or a Serotonin-Norepinephrine Reuptake Inhibitor (“SNRI”) and has no reuptake inhibition activity. EXXUA also exhibits no significant adverse effects on weight, blood pressure, heart rate or liver function. We successfully launched EXXUA in fiscal 2026 as the centerpiece of our commercial efforts. It is our expectation that EXXUA has the potential to serve as a major growth catalyst for us.
In addition, we will continue to focus on commercializing innovative prescription products that address other CNS conditions, including ADHD. We are focusing our efforts on accelerating the growth of our commercial business and achieving positive operating cash flows. To achieve these goals, we indefinitely suspended active development of our clinical development programs and have wound down and divested unprofitable operations.
Our business is focused on the growth of EXXUA and on our current prescription pharmaceutical products sold primarily through third-party wholesalers, distributors and pharmacies and which primarily consists of three product portfolios. The first consists of EXXUA for the treatment of MDD; the second, the ADHD Portfolio, consists of products for the treatment of ADHD; and the third, the Pediatric Portfolio, consists of a line of legacy products. We contract with CMOs for the manufacture and testing of all of our products.
We have entered into an exclusive international collaboration, distribution and supply agreement to commercialize certain of our ADHD products with Lupin, a subsidiary of global pharmaceutical company Lupin Limited, which will commercialize the ADHD products in Canada. We will supply the ADHD products to Lupin based on forecasts and provide various product commercialization, regulatory and quality assurance resources. Lupin is responsible for seeking local regulatory approvals and marketing authorizations for the ADHD products, which is expected to occur within the next year; however, there can be no guarantee that local regulatory approvals and marketing authorizations will be obtained on the expected timeline.
Management and our Board of Directors regularly review our performance, prospects and risks, including the potential effects of generic competition, payer pressures and new branded entrants. In connection with these reviews, we may evaluate partnerships, collaborations, acquisitions, divestitures and other strategic transactions that we believe could enhance stockholder value.
Agreement and Plan of Merger
On November 16, 2026, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”) and a wholly owned subsidiary of Rosemont. Pursuant to the Merger Agreement, Rosemont will acquire us through a cash tender offer for all outstanding shares of our common stock (the “Offer”) at a price of $2.70 per share in cash, followed by a merger in which we will become a wholly owned subsidiary of Rosemont (the “Merger” and, together with the Offer, the “Transaction”).
The completion of the Transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of our common stock and other customary conditions. Subject to the satisfaction or waiver of the applicable closing conditions, the parties expect the Transaction to close by the end of the calendar year.
The Merger Agreement contains customary representations, warranties and covenants, including restrictions on the operation of our business pending completion of the Transaction, as well as customary termination provisions. If the Transaction is completed, our common stock will cease to be publicly traded.
See “Part II, Item 1A. Risk Factors” below for certain risks related to the Transaction.
Business Environment
We continue to experience inflationary pressures and economic uncertainty caused by global geopolitical factors, trade wars and tariffs, and our industry is currently encountering supply chain disruptions related to the sourcing of raw materials, increased costs of materials as a result of tariffs, energy, logistics and labor for a number of reasons, including ongoing geopolitical events. It is possible that trade wars and economic or political policies could adversely affect some of our markets and suppliers, economic and financial markets, costs and availability of energy and materials, or cause further supply chain disruptions. Inflationary pressures, increased costs and supply chain disruptions could be significant across the business throughout fiscal 2027 and into fiscal 2028. Despite these risks, we have not experienced stock outages for our EXXUA or ADHD products since the launch of those products, and the pediatric product supply has remained adequate to satisfy demand.
In October 2024, we received the Notice Letter from Granules, stating that it intends to market a generic version of Adzenys before the expiration of all patents currently listed in the Orange Book. The Notice Letter stated that Granules’ ANDA for the generic version of Adzenys contains a Paragraph IV certification alleging that these patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic version of Adzenys. We timely filed a patent infringement lawsuit on December 11, 2024, against Granules to trigger a stay precluding the FDA from approving Granules’ ANDA for a generic version of Adzenys for up to 30 months or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. On January 7, 2025, Granules submitted an answer to the complaint. On June 27, 2025, the Court entered a Stipulation And Order Regarding Infringement finding that the submission of Granules’ ANDA infringed multiple claims in each of our asserted patents. On October 28, 2025, the case was reassigned to visiting judge, Judge Jennifer Choe-Groves of the United States Court of International Trade. The case is ongoing. The trial date has been moved to January 12, 2027. We plan to continue vigorously enforcing our intellectual property rights related to Adzenys.
Results of Operations
Our results of operations for the three months ended September 30, 2026, and 2025, were as follows:
| Three Months Ended |
||||||||||||
| September 30, |
||||||||||||
| 2026 |
2025 |
Change |
||||||||||
| (in thousands) |
||||||||||||
| Net revenue |
$ | 14,842 | $ | 13,888 | $ | 954 | ||||||
| Cost of goods sold |
5,405 | 4,702 | 703 | |||||||||
| Gross profit |
9,437 | 9,186 | 251 | |||||||||
| Operating expenses: |
||||||||||||
| Selling and marketing |
6,620 | 5,322 | 1,298 | |||||||||
| General and administrative |
5,985 | 4,924 | 1,061 | |||||||||
| Amortization of intangible assets |
761 | 444 | 317 | |||||||||
| Total operating expenses |
13,366 | 10,690 | 2,676 | |||||||||
| Loss from operations |
(3,929 | ) | (1,504 | ) | (2,425 | ) | ||||||
| Other income, net |
180 | 201 | (21 | ) | ||||||||
| Interest expense |
(408 | ) | (516 | ) | 108 | |||||||
| Derivative warrant liabilities gain |
276 | 3,784 | (3,508 | ) | ||||||||
| Total other income (expense), net |
48 | 3,469 | (3,421 | ) | ||||||||
| (Loss) income before income tax expense |
(3,881 | ) | 1,965 | (5,846 | ) | |||||||
| Income tax (expense) benefit |
— | — | — | |||||||||
| Net (loss) income |
$ | (3,881 | ) | $ | 1,965 | $ | (5,846 | ) | ||||
Net Revenue by Product Portfolio
Net revenue disaggregated by product portfolios for the three months ended September 30, 2026, compared to the three months ended September 30, 2025, is as follows:
| Three Months Ended |
||||||||||||
| September 30, |
||||||||||||
| 2026 |
2025 |
Change |
||||||||||
| (in thousands) |
||||||||||||
| EXXUA |
$ | 4,900 | $ | — | $ | 4,900 | ||||||
| ADHD Portfolio |
7,737 | 13,156 | (5,419 | ) | ||||||||
| Pediatric Portfolio |
2,205 | 715 | 1,490 | |||||||||
| Other |
— | 17 | (17 | ) | ||||||||
| Total net revenue |
$ | 14,842 | $ | 13,888 | $ | 954 | ||||||
Net revenue increased $1.0 million, or 6.9%, for the three months ended September 30, 2026, compared with the corresponding prior-year period, driven by $4.9 million of EXXUA net revenue and a $1.5 million increase in Pediatric Portfolio net revenue, partially offset by a $5.4 million decrease in ADHD Portfolio net revenue. The ADHD Portfolio decrease primarily reflected reduced promotional emphasis as commercial resources shifted towards EXXUA and the launch of a generic version of one of our ADHD products during the second quarter of fiscal 2026. The Pediatric Portfolio increase primarily reflected improved payer mix and lower returns compared with the prior-year period.
Gross Profit
Gross profit and gross profit percentage for the three months ended September 30, 2026, compared to the three months ended September 30, 2025, are as follows:
| Three Months Ended |
||||||||||||
| September 30, |
||||||||||||
| 2026 |
2025 |
Change |
||||||||||
| (in thousands, except gross profit percentage) |
||||||||||||
| Gross profit |
$ | 9,437 | $ | 9,186 | $ | 251 | ||||||
| Gross profit percentage |
64 | % | 66 | % | (2 | )% | ||||||
During the three months ended September 30, 2026, gross profit increased by $0.3 million, or 2.7%, compared to the same period ended September 30, 2025. Gross profit percentage was 64% for the three months ended September 30, 2026, compared to 66% for the same period ended September 30, 2025. Although gross profit percentage decreased by two percentage points, the increase in gross profit is the result of higher net revenue, partially offset by an increase in royalty expense included in cost of goods sold, primarily related to EXXUA.
Selling and Marketing
Selling and marketing expense increased $1.3 million, or 24.4%, for the three months ended September 30, 2026, compared with the corresponding prior-year period. The increase was primarily attributable to higher labor and travel costs associated with the commercialization of EXXUA. These increases were partially offset by lower health insurance premiums and lower processing costs and redemption fees resulting from a decline in ADHD Portfolio gross revenue. While total gross revenue decreased compared with the prior-year period, net revenue increased due to a shift in product mix toward EXXUA and the resulting improvement in gross-to-net realization.
General and Administrative
General and administrative expense increased $1.1 million, or 21.5%, for the three months ended September 30, 2026, compared with the corresponding prior-year period. The increase was primarily attributable to higher legal costs, largely due to our ongoing litigation with respect to the Granules Paragraph IV matter (see Business Environment above for additional information) and legal and consulting expenses incurred in connection with the Transaction, as well as a cancellation charge we incurred with one of our CMOs, partially offset by lower health insurance premiums.
Amortization of Intangible Assets
Amortization expense of intangible assets, excluding amounts included in cost of goods sold, increased $0.3 million, or 71.4%, for the three months ended September 30, 2026, compared with the corresponding prior-year period. The increase was primarily attributable to the amortization of intangible assets placed into service in connection with the EXXUA launch during the second quarter of fiscal 2026.
Other Income, Net
Other income, net, was substantially unchanged for the three months ended September 30, 2026, compared with the corresponding prior-year period.
Interest Expense
Interest expense decreased $0.1 million, or 20.9%, for the three months ended September 30, 2026, compared with the corresponding prior-year period, primarily due to the repayment of our fixed payment arrangements.
Derivative Warrant Liabilities Gain
The fair value of derivative warrant liabilities is calculated using the Black-Scholes option pricing model and is revalued at each reporting period, and changes are reflected through income or expense. For the three months ended September 30, 2026, we recognized a gain of $0.3 million from the fair value adjustment primarily driven by a decline in the volatility of our stock price. For the three months ended September 30, 2025, we recognized a gain of $3.8 million from the fair value adjustment primarily driven by a decrease in our stock price during the three months ended September 30, 2025.
Income Tax (Expense) Benefit
For the three months ended September 30, 2026, and 2025, there was no income tax expense, which resulted in an effective tax rate of zero. This was primarily driven by operating losses and favorable deductions under the OBBBA coupled with existing valuation allowances and adjustments from our income tax return filings.
Liquidity and Capital Resources
Sources of Liquidity
Our principal liquidity requirements include obligations under our loan agreements, potential milestone payments for licensed products and manufacturing purchase commitments, as well as the $3.0 million Second Payment due to Fabre-Kramer in the third quarter of fiscal 2027. We fund our operations with cash generated from operations, borrowings under our revolving credit facility and, when available, proceeds from equity financings. The Merger Agreement restricts our ability to incur additional indebtedness and to issue equity securities without Rosemont’s consent while the Transaction is pending. If the Transaction is completed, we expect the Eclipse Agreement to be repaid and terminated, including payment of the applicable early termination fees described in Note 10 - Revolving Credit Facility and Note 11 - Debt. We believe our existing cash and cash equivalents, cash flows from operations and availability under the Eclipse Revolving Loan will be sufficient to fund our operations and meet our obligations for at least the next 12 months.
Shelf Registrations
On September 26, 2024, we filed the 2024 Shelf registration statement on Form S-3, which was declared effective by the SEC on October 15, 2024. The shelf registration statement covers the offering, issuance and sale by us of up to an aggregate of $100.0 million of our common stock, preferred stock, debt securities, warrants, rights and units. Through the filing date of this Form 10-Q, $100.0 million remains available under the 2024 Shelf. This availability is subject to the SEC’s “baby shelf” limitation as set forth in General Instruction I.B.6 of Form S-3.
Eclipse Agreement
Under our Eclipse Agreement, we have two loan agreements, the Eclipse Term Loan and the Eclipse Revolving Loan. The Eclipse Term Loan consists of an outstanding principal amount of $13.0 million on the closing date of the Eclipse Amendment No. 6, at an interest rate of the SOFR plus 7.0%, with a four-year term and a straight-line loan amortization repayment schedule that results in a loan balance at the end of the four-year term of $5.6 million to be repaid on the June 12, 2029, maturity date, as amended. In June 2024, we used the initial proceeds from the Eclipse Term Loan and a portion of the proceeds from certain warrant exercises to repay in full a then-outstanding $15.0 million term loan. The Eclipse Revolving Loan has a potential maximum borrowing base of $14.5 million at an interest rate of the SOFR plus 4.5%, which was temporarily increased pursuant to the $1.5 million Eclipse Incremental Advance, with repayment and permanent reduction of the Eclipse Incremental Advance commencing on August 1, 2025, and continuing on the first day of each calendar month thereafter, in an amount equal to $125,000 per month, until the Eclipse Incremental Advance has been reduced to zero. As of June 30, 2026, the amount outstanding on the Eclipse Incremental Advance was $0.1 million, which was paid off in July 2026. In addition, we are required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan amount during the immediately preceding month. The ability to make borrowings and obtain advances of the Eclipse Revolving Loan remains subject to a borrowing base and reserve, and availability blockage requirements, and the maturity date, as amended, is June 12, 2029. Please refer to Note 10 - Revolving Credit Facility and Note 11 - Debt in Part I, Item 1 of this Form 10-Q for further information.
Cash Flows
The following table shows cash flows for the three months ended September 30, 2026, and 2025:
| Three Months Ended September 30, |
||||||||||||
| 2026 |
2025 |
Change |
||||||||||
| (in thousands) |
||||||||||||
| Net cash from operating activities |
$ | (275 | ) | $ | (618 | ) | $ | 343 | ||||
| Net cash from financing activities |
$ | (539 | ) | $ | 2,296 | $ | (2,835 | ) | ||||
Net Cash From Operating Activities
Net cash used in operating activities for the three months ended September 30, 2026, was $0.3 million, reflecting net loss of $3.9 million, adjusted for non-cash items of $1.4 million and a $1.5 million decrease in accrued liabilities, partially offset by decreases of $2.4 million in accounts receivable, $0.5 million in prepaid expenses and other current assets, and $0.5 million in inventories.
During the three months ended September 30, 2025, net cash used in operating activities totaled $0.6 million, which was primarily the result of an increase in accounts receivable, net and a decrease in accrued liabilities as well as negative cash earnings (derivative warrant liabilities adjustment partially offset by net income of $2.0 million, non-cash depreciation and amortization, stock-based compensation expense, and inventory write-down), partially offset by a decrease in inventories and an increase in accounts payable.
Net Cash From Investing Activities
There were no cash flows from investing activities for the three months ended September 30, 2026, and 2025.
Net Cash From Financing Activities
Net cash used in financing activities was $0.5 million for the three months ended September 30, 2026, consisting of principal payments on the Eclipse Term Loan and net repayments under the Eclipse Revolving Loan.
Net cash provided by financing activities of $2.3 million during the three months ended September 30, 2025, was primarily $5.8 million of net proceeds from our Eclipse Revolving Loan, partially offset by $3.1 million of payments for fixed payment arrangements and $0.5 million of payments made against the principal balance of our Eclipse Term Loan.
Contractual Obligations, Commitments and Contingencies
As a result of our acquisitions, exclusive commercialization agreement, and licensing agreements, we are contractually and contingently obligated to pay, when due, various contingent milestone payments. See Note 13 - Commitments and Contingencies in Part I, Item 1 of this Form 10-Q for further information.
In May 2022, we entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018, related to Tuzistra (the “Tuzistra License Agreement”). Pursuant to such termination we accrued a settlement liability, which was paid in full during the first quarter of fiscal 2026.
In connection with our suspension of active development of AR101 (enzastaurin) (“AR101”), we engaged in negotiations with EnzCo, LLC (“EnzCo”) and Rumpus VEDS LLC, (“Rumpus VEDS”), Rumpus Therapeutics LLC, (“Rumpus Therapeutics”) and Rumpus Vascular LLC, (“Rumpus Vascular” and, together with Rumpus VEDS and Rumpus Therapeutics, “Rumpus”) for the repurchase of AR101. In the first quarter of fiscal 2026, we reached terms with Rumpus and EnzCo whereby for mutual consideration and releases, we transferred all rights, title and interest in AR101 held by us and Rumpus to EnzCo, which extinguished and terminated all of our obligations and Rumpus’ obligations under the April 21, 2021, asset purchase agreement by and between us and Rumpus (the “Rumpus Asset Purchase Agreement”). There is no other relationship between us, EnzCo or Rumpus other than as contracting parties to terminate the Rumpus Asset Purchase Agreement, and there are no penalties or remaining obligations for us for terminating the Rumpus Asset Purchase Agreement.
Critical Accounting Estimates
The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a detailed discussion about our critical accounting estimates, refer to our 2026 Form 10-K.
Off-Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide information under this item.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As required by Rules 13a-15(e) and 15d-15(e) under the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2026, at reasonable assurance levels, in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Accordingly, we believe that the financial statements presented in this Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented herein.
Inherent Limitations on Effectiveness of Internal Controls over Financial Reporting
Our management team, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple errors or mistakes. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.
Changes in Internal Control over Financial Reporting
There have been no changes to our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, we become involved in or are threatened with legal disputes arising from our business and operations in the normal course of business. Most of these disputes are not likely to have a material effect on our business, financial condition, or operations. There were no new material legal proceedings that were initiated or terminated during the period covered by this report and there have been no material developments in the material proceedings identified in Part I, Item 3 in our 2026 Form 10-K. For a description of our material pending legal proceedings, see Note 13 - Commitments and Contingencies of the notes to the unaudited condensed consolidated financial statements included in Part I, Item 1 of this Form 10-Q, which is incorporated herein by reference. As of the filing of this report, no legal proceedings are pending against us that we believe individually or collectively are likely to have a material adverse effect upon our financial condition, results of operations, or cash flows.
ITEM 1A. RISK FACTORS
Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business prospects, financial condition, and results of operations, and you should carefully consider them. Except as set forth below, there have not been any material changes to our risk factors from those reported in our 2026 Form 10-K.
Risks Related to the Transaction
The Transaction may not be completed on the expected timeline or at all, which could adversely affect our business, financial condition, results of operations and the market price of our common stock.
The Offer is subject to the tender of a majority of the outstanding shares of our common stock and other customary closing conditions. Completion of the Transaction depends on the satisfaction or waiver of these and any other applicable conditions. If the conditions are not satisfied or waived, to the extent waivable, within the time periods contemplated by the Merger Agreement, the Offer or Merger may be delayed or may not be completed. In addition, the Merger Agreement may be terminated under certain specified circumstances. As a result, we cannot assure you that the Transaction will be completed, or that, if completed, it will be completed within the expected timeframe or on the terms currently contemplated.
If the Transaction is not completed within the expected timeframe or at all, we may be subject to a number of material risks. The failure to complete the Transaction may result in negative publicity and adversely affect our relationships with our stockholders, employees, customers, suppliers and other business partners. We may also be required to devote significant time and resources to litigation or other matters relating to any failure to complete the Transaction or the enforcement of our obligations under the Merger Agreement.
If the Transaction is not completed, our stockholders will not receive the consideration contemplated by the Merger Agreement, and the market price of our common stock could decline significantly.
If the Offer is consummated and the Merger is completed, our stockholders will be entitled to receive $2.70 per share of our common stock, subject to the terms of the Merger Agreement. If the Transaction is not completed for any reason, our stockholders will not receive such consideration, and we will remain an independent public company. In such circumstances, the market price of our common stock may decline significantly, particularly to the extent that the current market price reflects an assumption that the Transaction will be completed or a premium associated with the consideration to be paid in the Transaction.
If the Transaction is not completed, our business also may be adversely affected by the failure to realize the anticipated benefits of the Transaction, the costs incurred in connection with the Transaction, disruption to our business and relationships with employees, customers, suppliers and other business partners, and the diversion of management’s time and attention during the pendency of the Transaction. In addition, there can be no assurance that another transaction offering comparable or more favorable consideration to our stockholders will be available or that we will otherwise be able to pursue an alternative transaction on terms favorable to us or our stockholders.
The pendency of the Transaction, including any extension of the Offer or other delay in completion of the Transaction, could adversely affect our business, employees and relationships with third parties.
The announcement and pendency of the Transaction may create uncertainty regarding our future operations and could adversely affect our business and relationships with third parties. Such uncertainty may adversely affect our ability to retain and recruit key employees and may cause current or prospective employees to experience uncertainty regarding their future roles with us. The pendency of the Transaction also could adversely affect our relationships with customers, suppliers and other business partners, including as a result of uncertainty regarding our future business operations.
The Offer may be extended under circumstances specified in the Merger Agreement. Any extension of the Offer or other delay in completing the Transaction could prolong and exacerbate these effects. These disruptions could adversely affect our business, financial condition, results of operations and prospects regardless of whether the Transaction is ultimately completed. The Merger Agreement provides for an end date of February 14, 2027. If the conditions to completion of the Transaction are not satisfied or waived, to the extent waivable, within the time available before the end date, the Transaction may not be completed.
The Transaction could divert management’s attention and resources from our ongoing business operations.
The Transaction has required, and is expected to continue to require, substantial management time and resources. Our management and employees may be required to devote significant time and attention to the Offer, the Merger and other matters relating to the Transaction that could otherwise have been devoted to our ongoing business operations, the execution of our business strategy and other opportunities that may be beneficial to us.
The diversion of management’s attention and other resources could adversely affect our business, financial condition and results of operations. These effects could be exacerbated if the Offer is extended, completion of the Merger is delayed or the Transaction is not ultimately completed.
The Merger Agreement restricts our ability to take certain actions while the Transaction is pending, which could limit our ability to operate our business and pursue opportunities.
The Merger Agreement requires us to conduct our business and operations in the ordinary course of business consistent with past practice and contains interim operating covenants, such as the minimum operating covenants, that restrict us from taking certain actions without Rosemont’s consent during the period prior to completion of the Transaction, subject to specified exceptions.
These restrictions may limit our ability to respond to changing business conditions, take strategic or operational actions that we might otherwise consider advisable, pursue business opportunities or transactions, or otherwise operate our business in the manner we would absent the Transaction. These restrictions could adversely affect our business, financial condition, results of operations or prospects, particularly if the Offer is extended, completion of the Merger is delayed or the Transaction is not completed.
The Merger Agreement contains restrictions on our ability to pursue alternative transactions, which could discourage competing acquisition proposals.
The Merger Agreement contains restrictions on our ability to solicit, initiate or knowingly facilitate or encourage certain competing acquisition proposals and to participate in discussions or negotiations regarding such proposals, subject to exceptions that allow the Board of Directors to meet its fiduciary obligations.
These restrictions, together with any applicable procedural requirements under the Merger Agreement, could discourage third parties from making competing acquisition proposals, including proposals that may be more favorable to our stockholders than the Transaction. Accordingly, these provisions could reduce the likelihood that our stockholders receive the benefit of a proposal that is more favorable than the Transaction.
If the Merger Agreement is terminated under certain circumstances, we may be required to pay a termination fee, which could adversely affect us and could discourage competing acquisition proposals.
If the Merger Agreement is terminated under certain specified circumstances, including if we terminate the Merger Agreement to enter into a definitive agreement with respect to a superior proposal or if Rosemont terminates the Merger Agreement following a change in the recommendation of our Board of Directors, we may be required to pay Rosemont a termination fee of $2.4 million. The potential obligation to pay a termination fee could discourage third parties from making competing acquisition proposals, including proposals that might otherwise be more favorable to our stockholders than the Transaction.
If the termination fee becomes payable, the payment of such fee could adversely affect our financial condition and available cash resources and our ability to execute our business plans if the Transaction is not completed.
The announcement and pendency of the Transaction may result in litigation or other legal proceedings that could delay or prevent completion of the Transaction and adversely affect us.
Transactions such as the Transaction frequently result in litigation, including litigation brought by stockholders. We may become subject to lawsuits or other legal proceedings relating to the Merger Agreement, the Offer, the Merger or actions taken by our Board of Directors in connection with the Transaction.
Any such litigation or proceeding could be costly and time-consuming, divert management’s attention and resources from our ongoing business operations and, depending on its outcome, could delay or prevent consummation of the Offer or completion of the Merger. We cannot predict the outcome of any such litigation or proceeding or the effect it may have on the Transaction or our business.
Developments relating to the Transaction could cause volatility in the trading price of our common stock, including a significant decline if the Offer or Merger is delayed, the Merger Agreement is terminated or the Transaction is not otherwise completed.
The market price of our common stock may be volatile as a result of developments relating to the Transaction, including market perceptions regarding the likelihood or timing of consummation of the Offer or completion of the Merger, any extension of the Offer, developments relating to the satisfaction of the conditions to the Offer or Merger, or any decision or event relating to termination of the Merger Agreement.
If the Offer or Merger is delayed, the Merger Agreement is terminated or the Transaction is not otherwise completed, the market price of our common stock could decline significantly. The market price of our common stock also may be affected by factors unrelated to our underlying business performance during the pendency of the Transaction.
We have incurred, and expect to continue to incur, significant costs and expenses in connection with the Transaction, regardless of whether the Transaction is completed, and these costs could adversely affect our financial condition and results of operations if the Transaction is not completed.
We have incurred, and expect to continue to incur, significant costs and expenses in connection with the Transaction, including legal, financial advisory and other professional fees and expenses. Substantially all of these costs and expenses may be payable regardless of whether the Transaction is completed.
There are a number of factors beyond our control that could affect the total amount or timing of these costs and expenses. If the Transaction is not completed, we will have incurred these costs without realizing the anticipated benefits of the Transaction, which could adversely affect our financial condition and results of operations.
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the quarter ended September 30, 2026, none of our directors or executive officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).
ITEM 6. EXHIBITS
| Exhibit No. |
Description |
|
| 31.1* |
Certification of the Chief Executive Officer of Aytu BioPharma, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
| 31.2* |
Certification of the Chief Financial Officer of Aytu BioPharma, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
| 32.1** |
Certification of the Chief Executive Officer and the Chief Financial Officer of Aytu BioPharma, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
| 101.INS* |
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
| 101.SCH* | Inline XBRL Taxonomy Schema Linkbase Document. | |
| 101.CAL* | Inline XBRL Taxonomy Calculation Linkbase Document. | |
| 101.DEF* | Inline XBRL Taxonomy Definition Linkbase Document. | |
| 101.LAB* | Inline XBRL Taxonomy Labels Linkbase Document. | |
| 101.PRE* | Inline XBRL Taxonomy Presentation Linkbase Document. | |
| 104* |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
* Filed herewith.
** Furnished herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AYTU BIOPHARMA, INC. |
|||
| Date: November 16, 2026 |
By: |
/s/ Joshua R. Disbrow |
|
| Joshua R. Disbrow |
|||
| Chief Executive Officer | |||
| (Principal Executive Officer) | |||
| Date: November 16, 2026 | By: | /s/ Ryan J. Selhorn | |
| Ryan J. Selhorn | |||
| Chief Financial Officer | |||
| (Principal Financial and Accounting Officer) | |||